Association between Health Insurance Type and Genetic Testing and/or Counseling for Breast and Ovarian Cancer

As genetic testing becomes increasingly incorporated into clinical practice to aid in both the diagnosis and risk assessment of genetic diseases, patients benefit from genetic counseling to support their understanding of test results either before and/or after genetic testing. Therefore, access to genetic testing and counseling is imperative for patient care. It is well established that health insurance coverage is a major determinant of access to health care in the United States as individuals without insurance are less likely to have a regular source of health care than their insured counterparts. Different health insurance plans and benefits also influence patients’ access to health care. Data on the association of health insurance and the uptake of genetic testing and/or counseling for cancer risk are limited. Using data from the National Health Interview Survey, we examined the uptake of genetic testing and/or counseling for breast/ovarian cancer risk by health insurance type. We found that only a small proportion of women undergo genetic testing and/or counseling for breast/ovarian cancer risk (2.3%), even among subgroups of women at risk due to family or personal history (6.5%). Women with health insurance were more likely to undergo genetic testing and/or counseling for breast/ovarian cancer risk, particularly those with military and private insurance plans, than those without health insurance after adjusting for various demographic, socioeconomic, and health risk covariates. Further investigations are needed to examine potential disparities in access and health inequities.

[1]  Christine Y. Lu,et al.  Genetic Testing and/or Counseling for Colorectal Cancer by Health Insurance Type , 2022, Journal of personalized medicine.

[2]  S. Keyhani,et al.  Access to Care, Cost of Care, and Satisfaction With Care Among Adults With Private and Public Health Insurance in the US , 2021, JAMA network open.

[3]  B. Karlan,et al.  Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  D. Uyar,et al.  Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers , 2021, The application of clinical genetics.

[5]  David K Jones,et al.  Changes In Health Insurance Coverage, Access To Care, And Income-Based Disparities Among US Adults, 2011-17. , 2020, Health affairs.

[6]  E. Kohn,et al.  Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Caplan,et al.  Genetic discrimination: emerging ethical challenges in the context of advancing technology , 2019, Journal of law and the biosciences.

[8]  M. Cabana,et al.  Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. , 2019, JAMA.

[9]  R. Green,et al.  Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries , 2019, Nature Medicine.

[10]  M. Dorschner,et al.  Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests , 2019, Journal of genetic counseling.

[11]  S. Roth What is genomic medicine? , 2019, Journal of the Medical Library Association : JMLA.

[12]  J. Blum,et al.  Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers , 2019, Proceedings.

[13]  Jennifer M. Taber,et al.  Genetic counseling, genetic testing, and risk perceptions for breast and colorectal cancer: Results from the 2015 National Health Interview Survey. , 2019, Preventive medicine.

[14]  Megan C. Roberts,et al.  Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey , 2019, Journal of personalized medicine.

[15]  J. Newhouse,et al.  Access to care among Medicaid and uninsured patients in community health centers after the Affordable Care Act , 2019, BMC Health Services Research.

[16]  Angela Mariotto,et al.  Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Anne Marie McCarthy Persistent underutilization of BRCA1/2 testing suggest the need for new approaches to genetic testing delivery. , 2019, Journal of the National Cancer Institute.

[18]  Rakesh R. Patel,et al.  Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Christine Y. Lu,et al.  Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer , 2018, Journal of personalized medicine.

[20]  Héctor E Alcalá,et al.  Insurance Type and Access to Health Care Providers and Appointments Under the Affordable Care Act , 2018, Medical care.

[21]  M. P. Douglas,et al.  Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  Alaa M Althubaiti,et al.  Information bias in health research: definition, pitfalls, and adjustment methods , 2016, Journal of multidisciplinary healthcare.

[23]  Julie O. Culver,et al.  Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. , 2016, Cancer genetics.

[24]  Zicheng Xu,et al.  Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review , 2016, Clinical Cancer Research.

[25]  Yuya Kobayashi,et al.  Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. , 2015, JAMA oncology.

[26]  L. Garrison,et al.  Economic incentives for evidence generation: promoting an efficient path to personalized medicine. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  M. D. Graf,et al.  Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers. , 2013, Personalized medicine.

[28]  S. Haga,et al.  Insurance Coverage Policies for Personalized Medicine , 2012, Journal of personalized medicine.

[29]  M. Bush,et al.  Multiple chronic conditions among adults aged 45 and over: trends over the past 10 years. , 2012, NCHS data brief.

[30]  Joshua P Cohen,et al.  Clinical and economic challenges facing pharmacogenomics , 2012, The Pharmacogenomics Journal.

[31]  Peter J Neumann,et al.  Personalized medicine: factors influencing reimbursement. , 2010, Health policy.

[32]  Susan M. Domchek,et al.  Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers , 2009, Journal of the National Cancer Institute.

[33]  V. Shavers,et al.  Racial and ethnic disparities in the receipt of cancer treatment. , 2002, Journal of the National Cancer Institute.

[34]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[35]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[36]  Sitao Wu,et al.  Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing , 2019, JAMA oncology.

[37]  Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. , 2017, Obstetrics and gynecology.

[38]  S. Modesitt,et al.  Hereditary breast and ovarian cancer syndrome , 2011, Definitions.

[39]  S. Markovic,et al.  Genetic testing in colorectal cancer , 2013 .